Please login to the form below

Not currently logged in
Email:
Password:

Cello Health expands with Defined Health acquisition

Builds US presence with biotech-focused strategy specialist

Cello HealthCello Health has strengthened its US operations with the acquisition of business development specialist Defined Health.

The agency brings a particular focus in biotech strategy solutions to Cello Health, adding to the group's current offering in global marketing research and customer insight, strategic consulting, and evidence and engagement services.

Defined Health will work closely with its new parent company in early asset development and commercialisation, with a particular focus on defining value for early-stage compounds. The firm is also set to boost Cello Health's US capabilities in communications and insight, as well as areas such as market access.

Stephen Highley, chairman of Cello Health, said: “Defined Health has achieved a strong reputation by working closely with clients to build and strengthen biotech development-stage assets.

“Understanding the commercial opportunity and applicability of early stage assets is of fundamental importance to our clients and Defined Health positions Cello Health to be able to deliver to this requirement."

Defined Health also brings its thought leadership programme to the healthcare group, which includes its annual Cancer Progress conference - now in its 27th year - and the Therapeutic Insight conferences that cover an array of therapy areas.

Defined Health's president and founder Ed Saltzman, said: “Cello Health's core capabilities both augment and powerfully synergize with our own and will serve to increase the value we can offer our clients through the full span of the development process from early development to commercial launch.

“We are extremely excited to be part of Cello Health.”

Article by
Rebecca Clifford

7th February 2017

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...